

# Sebastian Zundler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7606527/publications.pdf>

Version: 2024-02-01

44  
papers

1,470  
citations

331670

21  
h-index

330143

37  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1978  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-12: Functional activities and implications for disease. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 559-568.	7.2	178
2	Differential effects of $\alpha 4 \beta 7$ and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. <i>Gut</i> , 2016, 65, 1642-1664.	12.1	138
3	Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. <i>Gut</i> , 2019, 68, 1688-1700.	12.1	108
4	Blockade of $\alpha 4 \beta 7$ integrin suppresses accumulation of CD8 <sup>+</sup> and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. <i>Gut</i> , 2017, 66, 1936-1948.	12.1	99
5	The $\alpha 4 \beta 7$ Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 379-391.	1.9	88
6	Non-classical monocyte homing to the gut via $\alpha 4 \beta 7$ integrin mediates macrophage-dependent intestinal wound healing. <i>Gut</i> , 2020, 69, 252-263.	12.1	80
7	Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer. <i>Vaccines</i> , 2016, 4, 5.	4.4	64
8	Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects. <i>Frontiers in Immunology</i> , 2017, 8, 891.	4.8	52
9	Intestinal Mucosal Wound Healing and Barrier Integrity in IBD—Crosstalk and Trafficking of Cellular Players. <i>Frontiers in Medicine</i> , 2021, 8, 643973.	2.6	52
10	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 508-524.	1.3	46
11	Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. <i>Frontiers in Immunology</i> , 2017, 8, 764.	4.8	42
12	Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 617-627.	1.9	39
13	Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver — case report and review of literature. <i>BMC Cancer</i> , 2016, 16, 130.	2.6	38
14	E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis. <i>Nature Cell Biology</i> , 2021, 23, 796-807.	10.3	38
15	Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S19-28.	0.8	36
16	BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 916-930.	8.2	34
17	Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1237-1250.	1.9	33
18	Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut. <i>Gastroenterology</i> , 2017, 153, 898-900.	1.3	27

#	ARTICLE	IF	CITATIONS
19	Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis. <i>Gut</i> , 2022, 71, 2414-2429.	12.1	26
20	Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 39.	3.5	25
21	Residual homing of $\alpha 4 \beta 7$ -expressing $\alpha 1 \beta 1$ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. <i>Gut</i> , 2022, 71, 1551-1566.	12.1	24
22	Pancreatic Panniculitis and Polyarthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 62.	4.7	23
23	Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders. <i>Immunological Reviews</i> , 2017, 278, 263-276.	6.0	20
24	Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. <i>Gut</i> , 2023, 72, 49-53.	12.1	18
25	Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 656452.	4.8	17
26	Severe Acute Respiratory Coronavirus 2 Attachment Receptor Angiotensin-Converting Enzyme 2 Is Decreased in Crohn's Disease and Regulated By Microbial and Inflammatory Signaling. <i>Gastroenterology</i> , 2021, 160, 925-928.e4.	1.3	15
27	Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482098280.	3.2	14
28	Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 103.	2.0	12
29	Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 33.	2.0	10
30	Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application. <i>American Journal of Gastroenterology</i> , 2018, 113, 1908-1910.	0.4	9
31	Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. <i>BMJ Open</i> , 2021, 11, e049208.	1.9	9
32	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker $\alpha 4 \beta 7$ Integrin Are Decreased in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 639329.	4.8	8
33	Total Recall: Intestinal TRM Cells in Health and Disease. <i>Frontiers in Immunology</i> , 2020, 11, 623072.	4.8	8
34	Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications. <i>Visceral Medicine</i> , 2020, 36, 129-136.	1.3	5
35	Dynamic Imaging of IEL-IEC Co-Cultures Allows for Quantification of CD103-Dependent T Cell Migration. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5148.	4.1	5
36	Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00494.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflammatory Bowel Diseases, 2022, 28, 1746-1755.	1.9	5
38	How will new and future therapies change our treatment of IBD?. Expert Review of Clinical Immunology, 2016, 12, 233-236.	3.0	3
39	Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. Journal of Visualized Experiments, 2018, , .	0.3	3
40	Vedolizumab blocks Î±4Î²7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210988.	3.2	3
41	Anti-trafficking agents in the treatment of inflammatory bowel disease. Current Opinion in Gastroenterology, 2019, 35, 499-506.	2.3	2
42	Vedolizumab-associated enthesitis: correlation or causality?. Rheumatology, 2021, 60, 5491-5492.	1.9	2
43	Î±4Î²7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110547.	3.2	1
44	Utilization of Diagnostic Imaging and Ionizing Radiation Exposureâ€”Has the Tide Already Turned?. Inflammatory Bowel Diseases, 2020, 26, 907-908.	1.9	0